Genomic and Proteomic Study of Richter Syndrome (CGPSR)

Central Hospital, Nancy, France

Status: Enrolling

Conditions: Richter Syndrome

Treatments: Other: Mass spectrometry; Genetic: RNA sequencing; Genetic: Whole exome sequencing.

Study type: Observational

Funder types: Other

Identifiers

NCT03619512

PSS2017/CGPSR-BROSÉUS/VS (Other Identifier)

2017-A01978-45

Details and patient eligibility

About

Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to chemorefractoriness.

This study aims at understanding the biological determinants of chemotherapy resistance in Richter Syndrome.

Full description

With the help of the French National Research Group on CLL (FILO / French Innovative Leukemia Organization), the investigators are currently gathering fresh frozen cell pellets at CLL stage, and lymph node biopsies at Richter stage. The investigators also gathered lymph node biopsies from DLBCL, as a reference group.

The investigators will perform genomic and proteomic comparative studies between CLL and Richter, as well as between Richter and primitive DLBCL, to understand the biological determinants of clonal evolution and chemorefractoriness of Richter Syndrom.

Enrollment: 170 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diagnosis of a Diffuse Large B-Cell Lymphoma arising in the context of a Chronic Lymphocytic Leukemia (group 1) or diagnosis of a primitive Diffuse Large B-Cell Lymphoma (group 2), or diagnosis of a Diffuse Large B-Cell Lymphoma arising in a context of small cells lymphoma, excluding CLL (group 3), or benefit from a diagnostic lymph node biopsy that did not reveal any tumor involvment (primitive or metastatic) (group 4).
• Patients must benefit from a lymph node biopsy at diagnosis.
• Patients must be followed by a FILO (French Innovative Leukemia Organization) member
• Histology of Diffuse Large B-Cell Lymphoma or Hodgkin histology.
• Suitable clinical data available.
• Samples must meet the following requirement :RIN (RNA Integrity Number) > 5 et DIN (DNA Integrity Number) > 6.5.

Exclusion criteria

• Samples that do not meet the inclusion criteria (insufficient clinical data, analysis impossible due to insufficient sample quality).

Trial design

170 participants in 4 patient groups

Richter Syndrom at diagnosis

Description:

patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.

Treatment:

Genetic: RNA sequencing

Other: Mass spectrometry

Genetic: Whole exome sequencing.

Primitive Diffuse Large B-Cell Lymphoma

Description:

patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.

Treatment:

Genetic: RNA sequencing

Other: Mass spectrometry

Genetic: Whole exome sequencing.

Other secundary Diffuse Large B-Cell Lymphoma

Description:

patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.

Treatment:

Genetic: RNA sequencing

Other: Mass spectrometry

Genetic: Whole exome sequencing.

Control group with no tumor involvment of lymph nodes

Description:

patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.

Treatment:

Genetic: RNA sequencing

Other: Mass spectrometry

Genetic: Whole exome sequencing.